Search Results | MSF Science Portal

Journal Article

|

Research

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, et al.

2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article

|

Letter

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P, et al.

2025-02-01 • IJTLD OPEN

Conference Material

|

Poster

Chavan V, Silsarma A, Khan S, Singh P, Iyer A, et al.

2024-11-08 • MSF Scientific Days Asia 2024

Journal Article

|

Research

Khan S, Silsarma A, Mahajan R, Davuluri P, Sutar N, et al.

2024-10-12 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

BACKGROUND

Tub...

Journal Article

|

Research

Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A, et al.

2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

BACKGROUND
World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberc...

Journal Article

|

Letter

Vengurlekar D, Walker C, Mahajan R, Dalal A, Chavan VV, et al.

2023-07-01 • International Journal of Tuberculosis and Lung Disease

Conference Material

|

Slide Presentation

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Abstract

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV, et al.

2023-06-07 • MSF Scientific Day International 2023

INTRODUCTION
Bedaquiline (BDQ) and linezolid (LZD) are Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A syst...

Conference Material

|

Poster

Singh SN, Singh P, Silsarma A, Iyer AS, Galindo MA, et al.

2022-11-30 • MSF Paediatric Days 2022

Journal Article

|

Research

Farooq HZ, Davies E, Brown B, Whitfield T, Tilston P, et al.

2021-07-01 • Journal of Infection

OBJECTIVES
SARS-CoV-2 emerged in South Asia in 2019 and has resulted in a global pandemic. Public Health England (PHE) Manchester rapidly escalated testing for SARS-CoV-2 in the high...

Conference Material

|

Poster

Mohan Kumar H, Lin Oo W, Gurung P, Spencer H, Shougrakpam J, et al.

2021-05-18 • MSF Scientific Days International 2021: Research

Science Portal

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

12-month post-treatment outcomes of previously treated drug-resistant tuberculosis patients subsequently treated with concomitant bedaquiline and delamanid +/-carbapenem, in Mumbai, India

Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study

Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India

Linezolid resistance in patients with drug-resistant TB

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Treatment outcomes among drug-resistant children below 10 years treated with newer drugs, in Médecins Sans Frontieres clinic in Mumbai, India

Real-world SARS CoV-2 testing in Northern England during the first wave of the COVID-19 pandemic

Secular trends in hepatitis C incidence in people living with HIV: analysis from a MSF cohort in Manipur, India